From: NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth
Characteristics | n | NAP1L1 expression | ||
---|---|---|---|---|
High | Low | p | ||
Age(year) | ||||
 < 50 | 43 | 15 (34.9%) | 28 (65.1%) | 0.067 |
 ≥ 50 | 54 | 10 (18.5%) | 44 (81.5%) | |
Clinical stage | ||||
 I | 8 | 1 (12.5%) | 7 (87.5%) | 0.025 |
 II | 53 | 9 (17.0%) | 44 (83.0%) | |
 III | 36 | 15 (41.7%) | 21 (58.3%) | |
Tumor scale | ||||
 ≤ 3 cm | 53 | 13 (24.5%) | 40 (75.5%) | 0.758 |
 > 3 cm | 44 | 12 (27.3%) | 32 (72.7%) | |
Histological grade | ||||
 I | 29 | 9 (31.0%) | 20 (69.0%) | 0.439 |
 II–III | 68 | 16 (23.5%) | 52 (76.5%) | |
Vital states | ||||
 Die | 26 | 13 (50.0%) | 13 (50.0%) | 0.001 |
 Alive | 71 | 12 (16.9%) | 59 (83.1%) | |
ER | ||||
 Negative | 36 | 12 (33.3%) | 24 (66.7%) | 0.191 |
 Positive | 61 | 13 (21.3%) | 48 (78.7%) | |
PR | ||||
 Negative | 40 | 14 (35.0%) | 26 (65.0%) | 0.082 |
 Positive | 57 | 11 (19.3%) | 46 (80.7%) | |
HER2 | ||||
 Negative | 60 | 15 (25.0%) | 45 (75.0%) | 0.825 |
 Positive | 37 | 10 (27.0%) | 27 (73.0%) | |
Lymph metastasis | ||||
 No | 32 | 6 (18.8%) | 26 (81.2%) | 0.267 |
 Yes | 65 | 19 (29.2%) | 46 (70.8%) |